Multidisciplinary Management of Patients with Basal Cell Carcinoma

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Soo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.

This publication highlights clinical perspectives on current treatment patterns in BCC, key findings from clinical trials, factors that influence clinical decision making, and opportunities for the development of novel therapies for this patient population.